Amgen researches treatments for aggressive lung cancer
Small cell lung cancer (SCLC) is an aggressive cancer with a poor prognosis. Amgen GmbH is investing in research for new treatment approaches.
Biotechnology company Amgen GmbH is focusing on researching new treatment approaches for small cell lung cancer (SCLC), one of the most aggressive and difficult-to-treat forms of cancer.
SCLC typically progresses rapidly and metastasizes early, yet is often diagnosed late. Five-year survival rates in advanced stages are below five percent. Therefore, early diagnosis and more effective, targeted treatments are critical to improving patient outcomes.
"Small cell lung cancer is highly aggressive. The tumor typically grows very quickly and forms metastases early, leaving a limited therapeutic window," explains Dr. Achim Rieth, Medical Director for Hematology & Oncology at Amgen GmbH. SCLC accounts for approximately 15–17 percent of all lung cancer cases.
Symptoms of SCLC, such as persistent cough or shortness of breath, are often non-specific and can be attributed to smoking, complicating early diagnosis. Approximately 70 percent of cases are diagnosed only after the cancer has spread. Treatment resistance and recurrence are significant challenges, with limited therapeutic options when the disease progresses.